Surg-21. Laser Ablation in Stereotactic Neurosurgery (laise): a Multi-institutional Retrospective Analysis of Litt for Newly Diagnosed and Recurrent Glioblastomas (gbms)
Year: 2017
Type: article
Study design: Observational Study
Abstract: Laser Interstitial Thermotherapy (LITT) is a minimally invasive procedure used to treat brain tumors. Here we present a retrospective series of 68 consecutive patients with GBMs treated at 9 centers. Retrospective, De-identified data on 34 primary and 34 recurrent GBMs treated with LITT. The demographics of the patients in both groups were similar with median patient age of 58.4 yrs.; male gender (55.8 %); pre-op KPS (82.7), and ECOG status (1). Other characteristics differed between the two groups however. The indications for LITT in newly diagnosed patients was more commonly “unresectable tumor” than recurrent GBMs treated with LITT (70.6% vs. 41.2%; p = 0.0146). Also, newly diagnosed GBMs treated with LITT were more commonly infratentorial (58.3% vs. 19.4 %; p =0.0021) or deep (63.9% vs. 27.8%; p = 0.0021), with larger median volumes (16.9 cm3 vs. 7.9 cm3; p= 0.0014) than GBMs at recurrence. Interestingly, the increased complexity of the newly diagnosed GBMs did not result in outcomes differences. Median lasing time (57.2 min), days to ambulation (2.3) and total stay (4.1 d) did not differ between the groups. Median ICU stay tended to be shorter in the recurrent group (20.7 hrs vs. 45.7 hrs; p =0.058), and the patients with recurrent GBM were discharged to home more commonly than patients with newly diagnosed GBM (75.8% vs. 51.5%; p = 0.0407). Median overall survival was similar in the two groups at 12 and 24 months (51% and 25.2% months respectively) with median follow-up of 244.6 days. LITT is safe and effective for the treatment of both newly diagnosed and recurrent glioblastomas with similar outcomes and survival. This may be explained in part by the increased complexity of the GBMs treated with LITT at time of diagnosis, which tended to be larger, deeper, and more often “unresectable.”
Source: Neuro-Oncology
Institutions: University Hospitals of Cleveland, Atrium Health Wake Forest Baptist, Thomas Jefferson University, The University of Texas MD Anderson Cancer Center, Saint Luke's Hospital, University of Missouri–Kansas City, The University of Kansas Health System, Yale University, Washington University in St. Louis
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2767410366